Synchronous effects of targeted mitochondrial complex I inhibitors on tumor and immune cells abrogate melanoma progression
Summary: Metabolic heterogeneity within the tumor microenvironment promotes cancer cell growth and immune suppression. We determined the impact of mitochondria-targeted complex I inhibitors (Mito-CI) in melanoma. Mito-CI decreased mitochondria complex I oxygen consumption, Akt-FOXO signaling, blocke...
Main Authors: | Mahmoud AbuEid, Donna M. McAllister, Laura McOlash, Megan Cleland Harwig, Gang Cheng, Donovan Drouillard, Kathleen A. Boyle, Micael Hardy, Jacek Zielonka, Bryon D. Johnson, R. Blake Hill, Balaraman Kalyanaraman, Michael B. Dwinell |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-06-01
|
Series: | iScience |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2589004221006210 |
Similar Items
-
Combining PEGylated mito-atovaquone with MCT and Krebs cycle redox inhibitors as a potential strategy to abrogate tumor cell proliferation
by: Gang Cheng, et al.
Published: (2022-03-01) -
Corrigendum to 'A review of the basics of mitochondrial bioenergetics, metabolism, and related signaling pathways in cancer cells: Therapeutic targeting of tumor mitochondria with lipophilic cationic compounds' [REDOX 14C (2017) 316–327]
by: Balaraman Kalyanaraman, et al.
Published: (2018-06-01) -
A review of the basics of mitochondrial bioenergetics, metabolism, and related signaling pathways in cancer cells: Therapeutic targeting of tumor mitochondria with lipophilic cationic compounds
by: Balaraman Kalyanaraman, et al.
Published: (2018-04-01) -
Teaching the basics of reactive oxygen species and their relevance to cancer biology: Mitochondrial reactive oxygen species detection, redox signaling, and targeted therapies
by: Balaraman Kalyanaraman, et al.
Published: (2018-05-01) -
Therapeutic Targeting of Tumor Cells and Tumor Immune Microenvironment Vulnerabilities
by: Balaraman Kalyanaraman, et al.
Published: (2022-06-01)